PMID- 24469650
OWN - NLM
STAT- MEDLINE
DCOM- 20141030
LR  - 20201005
IS  - 1735-546X (Electronic)
IS  - 1735-1308 (Linking)
VI  - 10
IP  - 4
DP  - 2014 Jan 4
TI  - The comparison between human leukocyte antigen system incidence in patients with 
      bladder cancer and normal controls.
PG  - 1059-62
AB  - PURPOSE: To determine the frequency of human leukocyte antigen (HLA)-B5 in 
      patients with bladder cancer compared with normal population. MATERIALS AND 
      METHODS: In this cross sectional study, from November 2009 until November 2010, 
      35 patients with pathologic diagnosis of bladder cancer who referred to urology 
      clinic of Razi Hospital were studied. Also, 130 healthy transplant donation 
      volunteers who referred for HLA-typing to Guilan Blood Transfusion Organization, 
      were selected. Inclusion criterion was pathologic diagnosis of bladder cancer 
      regardless of stage and grade of tumor. Exclusion criteria were presence of other 
      urologic diseases. The information of these cases was extracted from medical 
      records, collected and analyzed. RESULTS: HLA-B5 was positive in 34.3% of the 
      patient group and in 39.2% of the controls. Statistical analysis showed no 
      significant association between HLA-B5 and bladder cancer (P = .15). There were 
      no significant differences between grade (P = .107) and relapse (P = .327)of 
      bladder tumor with presence of HLA-B5. CONCLUSION: There was no significant 
      association between HLA-B5 and bladder cancer. The grade and the relapse of tumor 
      had no association with presence or absence of HLA-B5.
FAU - Falahatkar, Siavash
AU  - Falahatkar S
AD  - Urology and Nephrology Research Center, Guilan University of Medical Sciences, 
      Rasht,Iran.
FAU - Donyamali, Hadiseh
AU  - Donyamali H
AD  - Urology Research Center, Guilan University of Medical Sciences. 
      hadiseh_donyamali@yahoo.com.
FAU - Joafshani, Mohammad Ali
AU  - Joafshani MA
AD  - Urology and Nephrology Research Center, Guilan University of Medical Sciences, 
      Rasht,Iran.
FAU - Shahrokhi Damavand, Reza
AU  - Shahrokhi Damavand R
AD  - Urology and Nephrology Research Center, Guilan University of Medical Sciences, 
      Rasht,Iran.
FAU - Hoda, Saba
AU  - Hoda S
AD  - Urology and Nephrology Research Center, Guilan University of Medical Sciences, 
      Rasht,Iran.
FAU - Esmaeili, Samaneh
AU  - Esmaeili S
AD  - Urology and Nephrology Research Center, Guilan University of Medical Sciences, 
      Rasht,Iran.
FAU - Gholamjani Moghaddam, Keivan
AU  - Gholamjani Moghaddam K
AD  - Urology and Nephrology Research Center, Guilan University of Medical Sciences, 
      Rasht,Iran.
FAU - Nikpour, Sara
AU  - Nikpour S
AD  - Urology and Nephrology Research Center, Guilan University of Medical Sciences, 
      Rasht,Iran.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20140104
PL  - Iran
TA  - Urol J
JT  - Urology journal
JID - 101286676
RN  - 0 (HLA-B Antigens)
RN  - 0 (HLA-B5 antigen)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Carcinoma, Transitional Cell/*blood
MH  - Case-Control Studies
MH  - Cross-Sectional Studies
MH  - Female
MH  - HLA-B Antigens/*blood
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Grading
MH  - Neoplasm Recurrence, Local/*blood
MH  - Neoplasm Staging
MH  - Urinary Bladder Neoplasms/*blood/pathology
EDAT- 2014/01/29 06:00
MHDA- 2014/10/31 06:00
CRDT- 2014/01/29 06:00
PHST- 2012/04/16 00:00 [received]
PHST- 2012/12/30 00:00 [accepted]
PHST- 2012/11/08 00:00 [revised]
PHST- 2014/01/29 06:00 [entrez]
PHST- 2014/01/29 06:00 [pubmed]
PHST- 2014/10/31 06:00 [medline]
AID - 1441 [pii]
PST - epublish
SO  - Urol J. 2014 Jan 4;10(4):1059-62.